The approach taps into long‑lasting immune memories from past infections and redirects them against cancer, potentially changing how stubborn, low‑mutation tumours are treated.
A dead end for many current immunotherapies
Immunotherapy has reshaped cancer care over the past decade, particularly drugs that block so‑called immune checkpoints such as PD‑1 and PD‑L1. These treatments release the brakes on T cells, allowing them to attack tumours more aggressively.
That progress comes with a big caveat. A large group of patients barely benefit at all. Their cancers carry very few mutations, so they produce only a small number of “neoantigens” – abnormal proteins that mark cancer cells as different from healthy tissue.
Without these flags, T cells see almost nothing suspicious. The cancer grows quietly, while still expressing high levels of PD‑L1, a molecule that actively shuts down nearby immune cells.
Many solid tumours manage a double trick: they stay bland enough to avoid detection, and at the same time overproduce PD‑L1 to suppress any T cells that get too close.
Researchers at Shenzhen Bay Laboratory and Peking University set out to break this impasse. Instead of waiting for rare cancer neoantigens to spark an immune response, they asked a different question: could they borrow immune memories from past viral infections and graft those memories onto the tumour itself?
Recycling old viral memories to fight new cancers
Most adults carry powerful T cell responses against common viruses such as cytomegalovirus (CMV), Epstein–Barr virus and even chickenpox. These “memory” T cells can persist for decades, patrolling the body for any trace of their old enemies.
In many people, CMV‑specific T cells make up a surprisingly large share of the total T cell pool. They react quickly, release inflammatory molecules and kill infected cells with precision.
The Chinese team’s idea sounds almost like immunological judo: redirect existing, virus‑trained T cells and make them treat cancer cells as if they were virus‑infected.
➡️ What it means when someone only talks about themselves all the time, according to psychology
➡️ I made this slow-roasted dish and it felt worth the wait
➡️ A kitten escapes from its pet store box to comfort a puppy, a moving moment
➡️ Goodbye air fryer : new kitchen gadget goes beyond frying with 9 different cooking methods
To do that, they designed a synthetic chimera called iVAC, short for “intratumoral vaccination chimera”. It is injected directly into tumours and is meant to act as a local vaccine plus an immune checkpoint disarmer, all in one molecule.
How iVAC forces tumours into the spotlight
Two jobs packed into one molecule
iVAC was engineered with two main functions that work together:
- It tags and destroys PD‑L1 on the surface of cancer cells.
- It forces those same cells to display a viral fragment recognised by CMV‑specific T cells.
The PD‑L1 part relies on a bioorthogonal chemistry method known as FnFSY. That technique allows chemists to perform highly selective reactions inside living organisms without disrupting normal biology. In this case, iVAC latches onto PD‑L1 and triggers its rapid breakdown inside the tumour cell.
Without PD‑L1, the local immune brakes are released. T cells that were previously paralysed by the checkpoint signal can wake up.
The second component, a short CMV‑derived epitope, is smuggled into the tumour cell and then processed by its internal machinery. The cell presents this viral piece on its surface through MHC class I molecules, just as it would during a real viral infection.
Under iVAC pressure, a cancer cell temporarily behaves like a virus‑infected cell, wearing a CMV “badge” that memory T cells instantly recognise.
In lab tests, this converted cancer cells into something resembling professional antigen‑presenting cells, a role typically reserved for dendritic cells. Proteomic and transcriptomic analyses showed activation of inflammatory pathways once iVAC was in play.
Mouse models and human tumour samples show promise
The researchers put iVAC through a series of experiments in mice engineered to express human PD‑L1, and on patient‑derived tumour clusters grown outside the body.
In mice, four intratumoral injections spaced three days apart were enough to shrink established tumours significantly. The treated tumours showed a surge of CD8+ T cells, the cytotoxic subtype that directly kills abnormal cells.
In human tumour clusters, a one‑week exposure to iVAC cut viability by up to 80% in some samples. Tumours in which more than 20% of cells expressed PD‑L1 responded best, suggesting that PD‑L1 levels could serve as a biomarker for selecting patients.
The team also measured key immune messengers produced by T cells after iVAC exposure. Levels of interferon‑gamma (IFN‑γ) and TNF‑alpha – both signals of a strong, targeted response – rose markedly among CMV‑specific T cells taken from patients.
Importantly for safety, biodistribution studies indicated that iVAC largely stayed put at the tumour site for at least 72 hours, limiting widespread exposure.
Reprogramming cancer cells into immune allies
From silent bystanders to antigen presenters
Beyond killing, iVAC pushed tumour cells into a new temporary identity. Once they started presenting viral epitopes, they also activated genes tied to interferon‑gamma signalling and the STING pathway, a core sensor of abnormal DNA and a driver of innate immunity.
That shift made the cells behave more like “APC‑like” cells, capable not just of being targets but also of helping activate fresh T cells that had never seen the virus before.
In co‑culture experiments, tumour cells treated with iVAC could stimulate naïve CD8+ T cells to proliferate and mature, alongside classic dendritic cells. This was seen across both mouse lines (such as MC38 and B16) and modified human cells.
Crucially, the team reported no signs of autoimmunity in treated mice. Histological checks found no structural damage in major organs, even after several weeks, suggesting that the immune redirection remained mainly confined to the tumour area.
Towards personalised, memory‑based immunotherapy
While the current prototype uses CMV, the concept is broader. In principle, the chimera could be re‑armed with epitopes from other common viruses like Epstein–Barr virus or seasonal flu, depending on each patient’s immune history.
That would represent a shift in personalisation. Instead of focusing solely on the genetics of the tumour, future oncologists might profile a patient’s past infections, then select the viral target for iVAC accordingly.
Therapy design could move from “what mutations does the tumour have?” to “which viral memories are strongest in this patient’s immune system?”
Key concepts patients may hear in clinic
- PD‑L1: A protein on many tumour cells that binds to PD‑1 on T cells and shuts them down, like pressing a brake pedal.
- Neoantigen: A protein fragment created by cancer‑specific mutations, absent from healthy cells, and often used as a target in immunotherapy.
- Memory T cell: A long‑lived T cell left behind after an infection or vaccination, ready to respond rapidly if the same pathogen appears again.
- Intratumoral injection: Delivering a drug straight into the tumour mass, which can boost local effects and reduce whole‑body side effects.
What this could look like for patients one day
If approaches like iVAC make it to the clinic, a typical pathway might start with a biopsy to measure PD‑L1 expression and profile existing antiviral T cells in the blood. Patients with strong CMV or EBV responses and PD‑L1‑high tumours could be prime candidates.
Treatment might involve a short series of injections directly into accessible tumours, potentially combined with standard PD‑1/PD‑L1 blocking antibodies or chemotherapy. The injections would aim to spark a local “micro‑vaccination” inside the tumour, then let activated T cells chase down remaining cancer cells elsewhere.
Risks would include local inflammation, fever and, in some cases, the possibility of over‑activating antiviral T cells, leading to flu‑like symptoms. Long‑term monitoring would be needed to make sure redirected immune responses do not drift towards healthy tissues expressing similar peptides.
On the benefit side, patients whose cancers currently sit in the “cold tumour” category – little mutation, low response to checkpoint inhibitors – could gain a realistic shot at meaningful responses, by turning their own viral history into a weapon.
Originally posted 2026-03-05 04:22:09.